The benefits and disbenefits associated with cultural ecosystem services of urban green spaces.

Cultural ecosystem services (CES) and disservices shape landscape planning policy to a huge extent. We focus on the benefits and disbenefits associated with CES. The study aimed to explore the co-occurrence of the benefits and disbenefits associated with CES as well as the relationship between spatial and landscape characteristics and specific benefits and disbenefits.

A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination.

Testing and vaccination have been major components of the strategy for combating the ongoing COVID-19 pandemic. In this study, we have developed a quantitative anti-SARS-CoV-2 spike (S1) IgG antibody assay using a fingerstick dried blood sample. We evaluated the feasibility of using this high-throughput and quantitative anti-SARS-CoV-2 spike (S1) IgG antibody testing assay in vaccinated individuals.

What Every Clinical Virologist Should Know About The VALID Act On Behalf of the Pan-American Society for Clinical Virology Clinical Practice Com.

In 2018, a bi-partisan proposed draft legislation called the Verifying Accurate, Leading-edge IVCT Development (VALID) Act was released by Representative Larry Bucshon (Republican-Indiana) and Diana DeGette, (Democrat-Colorado). The VALID Act attempts to create a new framework for the oversight and regulations of both laboratory-developed testing procedures (commonly known as laboratory-developed tests) and In vitro diagnostic tests by the U.S.

Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test.

Background: Sensitive and high throughput molecular detection assays are essential during the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vast majority of the SARS-CoV-2 molecular assays use nasopharyngeal swab (NPS) or oropharyngeal swab (OPS) specimens collected from suspected individuals. However, using NPS or OPS as specimens has apparent drawbacks, e.

CLIA-waived molecular influenza testing in the emergency department and outpatient settings.

Respiratory tract infections are a common cause of visits to emergency departments and outpatient settings. Infections with influenza viruses A and B in particular, are responsible for significant morbidity and mortality in both pediatric and adult populations worldwide. A significant number of influenza diagnoses occur in the emergency departments with many being performed using rapid influenza diagnostic tests (RIDT) which have sensitivities as low as 30% depending on the specific RIDT and patient population.

Molecular diagnostics: harmonization through reference materials, documentary standards and proficiency testing.

There is a great need for harmonization in nucleic acid testing for infectious disease and clinical genetics. The proliferation of assay methods, the number of targets for molecular diagnostics and the absence of standard reference materials contribute to variability in test results among laboratories. This article provides a comprehensive overview of reference materials, related documentary standards and proficiency testing programs.

International standards and reference materials for quantitative molecular infectious disease testing.

The utility of quantitative molecular diagnostics for patient management depends on the ability to relate patient results to prior results or to absolute values in clinical practice guidelines. To do this, those results need to be comparable across time and methods, either by producing the same value across methods and test versions or by using reliable and stable conversions. Universally available standards and reference materials specific to quantitative molecular technologies are critical to this process but are few in number.

Using standards and controls in molecular assays for infectious diseases.

Ten years ago, laboratory directors introducing molecular infectious disease diagnostics in the routine clinical setting had few resources to assist in their implementation and quality assurance programs. In the past 10 years, several organizations have recognized this need and have established standard reference materials, controls, external quality assessment programs, and written guidelines. It is a challenge for the clinical laboratory scientist to evaluate and incorporate these new programs and services in the context of traditional good laboratory practice and current laboratory regulations.

HIV-1 PCR and isolation in seroconverting and seronegative homosexual men: absence of long-term immunosilent infection.

The presence of detectable HIV-1 prior to the appearance of HIV-1-specific antibody was assessed in 41 incident infections that occurred during a 6-year prospective cohort study. All available antibody-negative samples (n = 138) and the first antibody positive sample (n = 41) were tested, under code, by the polymerase chain reaction (PCR) in two laboratories and by HIV-1 isolation in a third laboratory. Samples were available as long as 66 months and at least 18 months before seroconversion for 24/41 subjects.

Detection of HIV-1 DNA by PCR: evaluation of primer pair concordance and sensitivity of a single primer pair.

Concordance between two primer pairs and the clinical sensitivity of a single primer pair-probe system were evaluated for a human immunodeficiency virus type 1 (HIV-1) polymerase chain reaction (PCR) assay. Six-hundred sixty-three clinically defined HIV-1 specimens were analyzed in a blind fashion for HIV-1 DNA using an optimized, well-characterized PCR assay. All samples were amplified in duplicate with each of two primer pairs targeting distinct, highly conserved regions within the HIV-1 gag genome.

A multicenter proficiency trial of gene amplification (PCR) for the detection of HIV-1.

The sensitivity and specificity of the polymerase chain reaction (PCR) for the detection of HIV-1 proviral DNA was determined in five laboratories with extensive experience in PCR testing. Five panels consisting of 105 HIV-1-seronegative specimens from regularly repeating blood donors with no risk factors for HIV infection and 99 HIV-1-seropositive and culture-positive specimens from a cohort of homosexual/bisexual men were sent under code to each laboratory. Amplification procedures and testing algorithms by which specimens were judged positive, negative, or indeterminate varied between laboratories.

HLA-DQ alpha allele and genotype frequencies in various human populations, determined by using enzymatic amplification and oligonucleotide probes.

Allele and genotype frequencies at the HLA-DQ alpha locus have been determined by the use of polymerase chain reaction (PCR) amplification and nonradioactive oligonucleotide probes. The probes define six alleles and 21 genotypes in a dot-blot format. A total of over 1,400 individuals from 11 populations has been typed by two different laboratories using this method.

The distribution of mutagenic activity in red, rose and white wines.

Using a modified Salmonella typhimurium TA98 Ames-test system, more than 150 red, white and rose wines were analyzed for direct-acting and microsomal enzyme-enhanced mutagenic activity. The following conclusions were reached from analysis of this wine mutagenicity data base. White and rose wines, as well as grape juices, exhibited little or no detectable direct-acting or microsomal enzyme-enhanced mutagenic activity.

Identification of prostate-specific antigen in the vaginal secretions of a male pseudohermaphrodite.

Prostatic glycoprotein was detected in the vaginal fluid of a male pseudohermaphrodite with use of an enzyme-linked immunosorbent assay. Following orchiectomy, prostatic glycoprotein concentrations fell from levels greater than 60 to less than 10.0 ng/ml.